Drug Trial Radar · NCT06816524
The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron Deficiency
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
324
Planned (sponsor's estimate)
Start
Mar 13, 2026
Primary completion
Dec 31, 2027
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- Nicole StoffelAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Jomo Kenyatta University of Agriculture and Technology; University of Oxford - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences; Radboud University Medical Center; National Institute for Public Health and the Environment (RIVM)
- First posted
- Feb 10, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months, up to 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Malaria and iron deficiency cause a significant burden of disease in Africa. Iron deficiency (ID) might affect immune responses to vaccination. In this double-blind randomized controlled trial, we aim to assess: (1) whether ID impairs R21/Matrix-M, Typhim VI and measles (MR) vaccine response, (2) whether iron treatment at time of vaccination improves vaccine response.
Conditions
- Iron Deficiencies
Interventions
Iron syrupDietary supplement
Iron syrup administered daily from 6 to 10 months of age.
Multivitamin syrupDietary supplement
Multivitamin syrup administered daily from 6 to 10 months of age.
R21-Matrix/M Vaccine (malaria vaccine)Biological
R21-Matrix/M vaccine administered in 3 doses at 7, 8 and 9 months of age.
Measles-Rubella vaccineBiological
Measles-Rubella vaccine administered at 9 months of age.
Primary outcomes
What the sponsor says the trial is designed to measure.
- NANP-specific IgGTime frame: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
- Anti-measles IgGTime frame: At 10 months of age (1 month after MR vaccine administration)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Msambweni District Hospital
Msambweni, Kwale County, Kenya · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.